Eisai files for full FDA approval for Alzheimer’s drug Leqembi

The logo of Eisai Co Ltd is displayed at the company headquarters in TokyoThe logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo

  • Eisai Co LtdFollow
  • Biogen IncFollow
  • U.S. Food and Drug AdministrationFollow

Jan 6 (Reuters) – Japanese drugmaker Eisai Co Ltd (4523.T) said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved under the agency's accelerated review process.

  • Future of HealthcategoryExclusive: China in talks with Pfizer for generic COVID drug – sources, article with image12:59 AM UTC
  • GalleryFuture of HealthcategoryEisai, Biogen receives U.S. FDA approval for Alzheimer's drug, applies for full approval, article with gallery6:10 AM UTC . Updated undefined ago
  • ApprovalscategoryFactbox: Who can get the newly approved Eisai and Biogen Alzheimer's drug?, article with imageJanuary 6, 2023
  • VideoGovernmentcategoryNow able to sell abortion pill, U.S. pharmacies weigh if they should, article with videoJanuary 6, 2023


Related posts

India lifts curbs on AmEx after compliance on data rules

Cynthia Danforth

Norway wealth fund posts record $164 bln loss

Cynthia Danforth

Iberia solves IT problem that delayed dozens of flights

Cynthia Danforth

Leave a Comment